|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PTPRG |
Gene summary for PTPRG |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PTPRG | Gene ID | 5793 |
| Gene name | protein tyrosine phosphatase receptor type G | |
| Gene Alias | HPTPG | |
| Cytomap | 3p14.2 | |
| Gene Type | protein-coding | GO ID | GO:0001667 | UniProtAcc | P23470 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5793 | PTPRG | CCI_1 | Human | Cervix | CC | 2.73e-09 | 1.54e+00 | 0.528 |
| 5793 | PTPRG | CCI_2 | Human | Cervix | CC | 7.17e-03 | 5.95e-02 | 0.5249 |
| 5793 | PTPRG | HTA11_347_2000001011 | Human | Colorectum | AD | 2.21e-04 | 4.75e-01 | -0.1954 |
| 5793 | PTPRG | HTA11_1391_2000001011 | Human | Colorectum | AD | 3.20e-10 | 1.01e+00 | -0.059 |
| 5793 | PTPRG | HTA11_5212_2000001011 | Human | Colorectum | AD | 7.90e-07 | -5.79e-01 | -0.2061 |
| 5793 | PTPRG | HTA11_4255_2000001011 | Human | Colorectum | SER | 2.45e-05 | 6.13e-01 | 0.0446 |
| 5793 | PTPRG | HTA11_9408_2000001011 | Human | Colorectum | AD | 2.69e-04 | -5.67e-01 | 0.0451 |
| 5793 | PTPRG | HTA11_99999970781_79442 | Human | Colorectum | MSS | 3.09e-06 | 5.68e-01 | 0.294 |
| 5793 | PTPRG | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 4.84e-27 | 1.41e+00 | 0.3487 |
| 5793 | PTPRG | HTA11_99999965104_69814 | Human | Colorectum | MSS | 3.64e-23 | 1.42e+00 | 0.281 |
| 5793 | PTPRG | A002-C-010 | Human | Colorectum | FAP | 1.18e-10 | 1.94e-01 | 0.242 |
| 5793 | PTPRG | A001-C-207 | Human | Colorectum | FAP | 7.38e-03 | 6.20e-02 | 0.1278 |
| 5793 | PTPRG | A015-C-203 | Human | Colorectum | FAP | 6.28e-38 | -5.88e-01 | -0.1294 |
| 5793 | PTPRG | A015-C-204 | Human | Colorectum | FAP | 4.24e-05 | -2.66e-01 | -0.0228 |
| 5793 | PTPRG | A014-C-040 | Human | Colorectum | FAP | 6.84e-03 | -3.22e-01 | -0.1184 |
| 5793 | PTPRG | A002-C-201 | Human | Colorectum | FAP | 5.35e-13 | -2.67e-01 | 0.0324 |
| 5793 | PTPRG | A001-C-119 | Human | Colorectum | FAP | 1.65e-13 | -6.36e-01 | -0.1557 |
| 5793 | PTPRG | A001-C-108 | Human | Colorectum | FAP | 1.81e-19 | -4.67e-01 | -0.0272 |
| 5793 | PTPRG | A002-C-205 | Human | Colorectum | FAP | 6.31e-30 | -6.61e-01 | -0.1236 |
| 5793 | PTPRG | A001-C-104 | Human | Colorectum | FAP | 2.54e-02 | -2.10e-01 | 0.0184 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:009013210 | Cervix | CC | epithelium migration | 90/2311 | 360/18723 | 2.45e-11 | 6.11e-09 | 90 |
| GO:00016679 | Cervix | CC | ameboidal-type cell migration | 110/2311 | 475/18723 | 2.66e-11 | 6.36e-09 | 110 |
| GO:001063110 | Cervix | CC | epithelial cell migration | 89/2311 | 357/18723 | 3.72e-11 | 8.54e-09 | 89 |
| GO:009013010 | Cervix | CC | tissue migration | 90/2311 | 365/18723 | 5.42e-11 | 1.05e-08 | 90 |
| GO:001063210 | Cervix | CC | regulation of epithelial cell migration | 72/2311 | 292/18723 | 4.52e-09 | 4.43e-07 | 72 |
| GO:00109757 | Cervix | CC | regulation of neuron projection development | 88/2311 | 445/18723 | 4.26e-06 | 1.09e-04 | 88 |
| GO:00064708 | Cervix | CC | protein dephosphorylation | 60/2311 | 281/18723 | 1.33e-05 | 2.68e-04 | 60 |
| GO:00512713 | Cervix | CC | negative regulation of cellular component movement | 73/2311 | 367/18723 | 2.22e-05 | 3.95e-04 | 73 |
| GO:00400133 | Cervix | CC | negative regulation of locomotion | 76/2311 | 391/18723 | 3.47e-05 | 5.60e-04 | 76 |
| GO:20001463 | Cervix | CC | negative regulation of cell motility | 71/2311 | 359/18723 | 3.47e-05 | 5.60e-04 | 71 |
| GO:00303363 | Cervix | CC | negative regulation of cell migration | 68/2311 | 344/18723 | 5.11e-05 | 7.70e-04 | 68 |
| GO:00313456 | Cervix | CC | negative regulation of cell projection organization | 39/2311 | 186/18723 | 5.86e-04 | 5.57e-03 | 39 |
| GO:00163117 | Cervix | CC | dephosphorylation | 73/2311 | 417/18723 | 1.23e-03 | 9.87e-03 | 73 |
| GO:00109775 | Cervix | CC | negative regulation of neuron projection development | 28/2311 | 137/18723 | 4.74e-03 | 2.83e-02 | 28 |
| GO:0016311 | Colorectum | AD | dephosphorylation | 123/3918 | 417/18723 | 1.84e-05 | 3.82e-04 | 123 |
| GO:0001667 | Colorectum | AD | ameboidal-type cell migration | 137/3918 | 475/18723 | 2.17e-05 | 4.33e-04 | 137 |
| GO:0006470 | Colorectum | AD | protein dephosphorylation | 88/3918 | 281/18723 | 2.56e-05 | 4.89e-04 | 88 |
| GO:0010975 | Colorectum | AD | regulation of neuron projection development | 129/3918 | 445/18723 | 2.88e-05 | 5.37e-04 | 129 |
| GO:0090132 | Colorectum | AD | epithelium migration | 105/3918 | 360/18723 | 1.18e-04 | 1.73e-03 | 105 |
| GO:0010632 | Colorectum | AD | regulation of epithelial cell migration | 88/3918 | 292/18723 | 1.19e-04 | 1.75e-03 | 88 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PTPRG | SNV | Missense_Mutation | c.253C>G | p.Pro85Ala | p.P85A | P23470 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A2-A0YH-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
| PTPRG | SNV | Missense_Mutation | rs768919412 | c.3137N>T | p.Ser1046Leu | p.S1046L | P23470 | protein_coding | deleterious(0) | probably_damaging(0.947) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| PTPRG | SNV | Missense_Mutation | novel | c.1472N>T | p.Ser491Phe | p.S491F | P23470 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AO-A03L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
| PTPRG | SNV | Missense_Mutation | c.391N>C | p.Asp131His | p.D131H | P23470 | protein_coding | deleterious(0) | probably_damaging(0.941) | TCGA-AR-A0TV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PTPRG | SNV | Missense_Mutation | c.3364N>A | p.Gly1122Arg | p.G1122R | P23470 | protein_coding | deleterious(0.05) | benign(0.019) | TCGA-B6-A0I8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| PTPRG | SNV | Missense_Mutation | c.3943N>G | p.Gln1315Glu | p.Q1315E | P23470 | protein_coding | deleterious(0.02) | benign(0.098) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| PTPRG | SNV | Missense_Mutation | c.2241N>C | p.Leu747Phe | p.L747F | P23470 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-E9-A22E-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphane | SD | |
| PTPRG | SNV | Missense_Mutation | novel | c.47T>G | p.Ile16Ser | p.I16S | P23470 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.84) | TCGA-EW-A6SA-01 | Breast | breast invasive carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| PTPRG | SNV | Missense_Mutation | novel | c.522N>T | p.Met174Ile | p.M174I | P23470 | protein_coding | deleterious(0.01) | benign(0.027) | TCGA-OL-A66N-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| PTPRG | SNV | Missense_Mutation | novel | c.663N>C | p.Leu221Phe | p.L221F | P23470 | protein_coding | deleterious(0) | probably_damaging(0.939) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 5793 | PTPRG | PROTEIN PHOSPHATASE, DRUGGABLE GENOME | inhibitor | 252827488 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |